#yourfavoritenews – “Rituximab Plus Velcade as An Effective Therapy for Non-Hodgkin’s Lymphoma Subtypes”



A Phase 2 clinical trial led by Dr. Kristie Blum at Ohio State University Comprehensive Cancer Center revealed encouraging results for the therapeutic combination of rituximab and Velcade in patients with specific subtypes of non-Hodgkin’s lymphoma. Read the article: http://bit.ly/1MAol7i


Tagged , , .

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

Leave a Comment

Your email address will not be published. Required fields are marked *